Cypress Cove Care Center | |
200 Alabama Avenue, Muscle Shoals, Alabama 35661 | |
(256) 381-4330 | |
Name | Cypress Cove Care Center |
---|---|
Location | 200 Alabama Avenue, Muscle Shoals, Alabama |
Certified By | Medicare and Medicaid |
No. of Certified Beds | 90 |
Occupancy Rate | 67.11% |
Medicare ID (CCN) | 015392 |
Legal Business Name | Sunbridge Healthcare Llc |
Ownership Type | For Profit - Corporation |
NPI Number | 1346291176 |
Organization Name | SUNBRIDGE HEALTHCARE LLC |
Doing Business As | CYPRESS COVE CENTER |
Address | 200 Alabama Ave., Muscle Shoals, AL 35661 |
Phone Number | 256-381-4330 |
News Archive
VIVUS, Inc. today announced that positive results from a pivotal phase 3 open-label clinical trial evaluating long-term safety and efficacy of the investigational drug avanafil for the treatment of erectile dysfunction were presented at the 2011 Annual Meeting of the American Urological Association in Washington, D.C.
SGLT2 inhibitors (gliflozins) were developed as oral antidiabetics. They enhance urinary glucose excretion by inhibiting SGLT-2 (sodium-dependent glucose co-transporter-2) in the renal tubuli.
Last December, researchers identified more than 1,000 gene mutations in individuals with autism, but how these mutations increased risk for autism was unclear. Now, UNC School of Medicine researchers are the first to show how one of these mutations disables a molecular switch in one of these genes and causes autism.
Stem cell research at the University of California, Riverside is about to gather speed thanks to the establishment of a new Stem Cell Core Facility (SCCF) - a shared facility providing infrastructure, equipment, and trained personnel for doing stem cell research that ordinarily would not be available in most laboratories.
› Verified 2 days ago
NPI Number | 1841685278 |
Address | 200 Alabama Ave, Muscle Shoals, AL 35661 |
Phone Number | 256-566-7963 |
News Archive
VIVUS, Inc. today announced that positive results from a pivotal phase 3 open-label clinical trial evaluating long-term safety and efficacy of the investigational drug avanafil for the treatment of erectile dysfunction were presented at the 2011 Annual Meeting of the American Urological Association in Washington, D.C.
SGLT2 inhibitors (gliflozins) were developed as oral antidiabetics. They enhance urinary glucose excretion by inhibiting SGLT-2 (sodium-dependent glucose co-transporter-2) in the renal tubuli.
Last December, researchers identified more than 1,000 gene mutations in individuals with autism, but how these mutations increased risk for autism was unclear. Now, UNC School of Medicine researchers are the first to show how one of these mutations disables a molecular switch in one of these genes and causes autism.
Stem cell research at the University of California, Riverside is about to gather speed thanks to the establishment of a new Stem Cell Core Facility (SCCF) - a shared facility providing infrastructure, equipment, and trained personnel for doing stem cell research that ordinarily would not be available in most laboratories.
› Verified 2 days ago
Ratings from Surveys (Inspections): | |
Ratings from Quality Measures: | |
Ratings from Staffing Data: | |
Overall Rating: |
---|
News Archive
VIVUS, Inc. today announced that positive results from a pivotal phase 3 open-label clinical trial evaluating long-term safety and efficacy of the investigational drug avanafil for the treatment of erectile dysfunction were presented at the 2011 Annual Meeting of the American Urological Association in Washington, D.C.
SGLT2 inhibitors (gliflozins) were developed as oral antidiabetics. They enhance urinary glucose excretion by inhibiting SGLT-2 (sodium-dependent glucose co-transporter-2) in the renal tubuli.
Last December, researchers identified more than 1,000 gene mutations in individuals with autism, but how these mutations increased risk for autism was unclear. Now, UNC School of Medicine researchers are the first to show how one of these mutations disables a molecular switch in one of these genes and causes autism.
Stem cell research at the University of California, Riverside is about to gather speed thanks to the establishment of a new Stem Cell Core Facility (SCCF) - a shared facility providing infrastructure, equipment, and trained personnel for doing stem cell research that ordinarily would not be available in most laboratories.
› Verified 2 days ago
Number of Facility Reported Incidents | 0 |
Number of Substantiated Complaints | 0 |
Number of Fines | 0 |
Total Amount of Fines in Dollars | $0 |
Number of Payment Denials | 0 |
Total Number of Penalties | 0 |
Experience Measure | Provider | National Avg. |
---|---|---|
Percentage of long-stay residents whose need for help with daily activities has increased | 11.26 | 14.46 |
Percentage of long-stay residents who lose too much weight | 11.68 | 5.51 |
Percentage of low risk long-stay residents who lose control of their bowels or bladder | 35.85 | 48.41 |
Percentage of long-stay residents with a catheter inserted and left in their bladder | 1.98 | 1.79 |
Percentage of long-stay residents with a urinary tract infection | 3.12 | 2.65 |
Percentage of long-stay residents who have depressive symptoms | 0 | 5.05 |
Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
Percentage of long-stay residents experiencing one or more falls with major injury | 3.27 | 3.36 |
Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 99.59 | 93.87 |
Percentage of long-stay residents who received an antipsychotic medication | 7.62 | 14.2 |
Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 71.91 | 83.88 |
Percentage of short-stay residents who newly received an antipsychotic medication | 3.57 | 1.79 |
Percentage of long-stay residents whose ability to move independently worsened | 19.56 | 17.09 |
Percentage of long-stay residents who received an antianxiety or hypnotic medication | 30.08 | 19.7 |
Percentage of high risk long-stay residents with pressure ulcers | 13.28 | 7.32 |
Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 98.39 | 95.98 |
Percentage of short-stay residents who made improvements in function | 68.52 | 67.99 |
Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 75.38 | 82.93 |
News Archive
VIVUS, Inc. today announced that positive results from a pivotal phase 3 open-label clinical trial evaluating long-term safety and efficacy of the investigational drug avanafil for the treatment of erectile dysfunction were presented at the 2011 Annual Meeting of the American Urological Association in Washington, D.C.
SGLT2 inhibitors (gliflozins) were developed as oral antidiabetics. They enhance urinary glucose excretion by inhibiting SGLT-2 (sodium-dependent glucose co-transporter-2) in the renal tubuli.
Last December, researchers identified more than 1,000 gene mutations in individuals with autism, but how these mutations increased risk for autism was unclear. Now, UNC School of Medicine researchers are the first to show how one of these mutations disables a molecular switch in one of these genes and causes autism.
Stem cell research at the University of California, Riverside is about to gather speed thanks to the establishment of a new Stem Cell Core Facility (SCCF) - a shared facility providing infrastructure, equipment, and trained personnel for doing stem cell research that ordinarily would not be available in most laboratories.
› Verified 2 days ago
Cypress Cove Care Center Location: 200 Alabama Avenue, Muscle Shoals, Alabama 35661 Phone: (256) 381-4330 |